Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma

被引：1
|
作者：
Abeykoon, Jithma P. [1 ]
Vaxman, Luliana [2 ]
Patel, Sanjay V. [2 ]
Kumar, Shaji [3 ]
Young, Kimberly S. [2 ]
Ailawadhi, Sikander [4 ]
Larsen, Jeremy T. [5 ]
Gonsalves, Wilson I. [6 ]
Kourelis, Taxiarchis [1 ]
Leung, Nelson [7 ]
Warsame, Rahma M. [1 ]
Hobbs, Miriam A. [1 ]
Fonder, Amie [1 ]
Hwa, Yi L. [1 ]
Bergsage, P. Leif [8 ]
Lacy, Martha Q. [6 ]
kumar, S. Vincent Raj [1 ]
Gertz, Morie A. [1 ]
Kapoor, Prashant [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Rochester, NY USA
[3] Mayo Clin, Rochester, MN USA
[4] Mayo Clin, Div Hematol, Jacksonville, FL USA
[5] Mayo Clin, Div Hematol, Phoenix, AZ USA
[6] Mayo Sch Grad Med Educ, Div Hematol, Rochester, MN USA
[7] Mayo Clin Rochester, Div Hematol, Rochester, MN USA
[8] Mayo Clin, Div Hematol, Scottsdale, AZ USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154183
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
    Yifei Zhang
    Amandeep Godara
    Stacey Pan
    Denis Toskic
    Hashim Mann
    Douglas Sborov
    Raymond Comenzo
    Ankit Kansagra
    Annals of Hematology, 2022, 101 : 2119 - 2121
  • [32] Multiple Myeloma Belantamab Mafodotin opens up New Treatment Perspective
    Sankawa, Yuri
    ACTA HAEMATOLOGICA, 2021, 144 (05) : 592 - 593
  • [33] A real-world study of belantamab mafodotin in a heavily pretreated population of multiple myeloma patients
    Bird, Sarah
    Bishop, Ellouise
    Panopoulou, Katerina
    Saso, Radovan
    Mir, Farheen
    Stern, Simon
    Kaiser, Martin
    Boyd, Kevin
    Pawlyn, Charlotte
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 60 - 61
  • [34] Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin
    Popat, Rakesh
    Badros, Ashraf Z.
    Kumar, Shaji
    Rodríguez-Otero, Paula
    Cohen, Adam D.
    Manier, Salomon
    Voorhees, Peter M.
    Gay, Francesca
    Rifkin, Robert M.
    Martin, Thomas
    Chari, Ajai
    Weisel, Katja
    Farooq, Asim V.
    Jeng, Bennie H.
    Chng, Wee Joo
    Lee, Hans C.
    Berdeja, Jesus
    Jadhav, Vinay
    Tosolini, Alessandra
    Eliason, Laurie
    Palumbo, Antonio
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Trudel, Suzanne
    Richardson, Paul G.
    Terpos, Evangelos
    BLOOD, 2021, 138
  • [35] EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
    Tzogani, Kyriaki
    Penttil, Karri
    Lahteenvuo, Johanna
    Lapvetelainen, Tuomo
    Lopez Anglada, Lucia
    Prieto, Carolina
    Garcia-Ochoa, Blanca
    Enzmann, Harald
    Gisselbrecht, Christian
    Delgado, Julio
    Pignatti, Francesco
    ONCOLOGIST, 2021, 26 (01): : 70 - 76
  • [36] Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review.
    Neupane, Karun
    Ehsan, Hamid
    Wahab, Ahsan
    Masood, Adeel
    Ahmed, Tehniat Faraz
    Bahram, Saman
    Hannan, Abdul
    Haider, Mobeen Zaka
    Shahzad, Moazzam
    Mushtaq, Muhammad Umair
    Anwer, Faiz
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
    David Gil-Sierra, Manuel
    Del Pilar Briceno-Casado, Maria
    Javier Julia-Luna, Francisco
    Dolores Martinez-Moya, Maria
    INDIAN JOURNAL OF PHARMACOLOGY, 2022, 54 (05) : 373 - 376
  • [38] Belantamab Mafodotin Combo Shows PFS Improvement in R/R Multiple Myeloma
    不详
    ONCOLOGY-NEW YORK, 2024, 38 (07):
  • [39] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Degli Esposti, Simona
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
  • [40] Soluble BCMA in tear fluids: a potential mechanism of ocular toxicity caused by Belantamab mafodotin
    Munawar, U.
    Theuersbacher, J.
    Steinhardt, M.
    Zhou, X.
    Vogt, C.
    Nerreter, S.
    Han, S.
    Regensburger, A. -K.
    Haertle, L.
    Teufel, E.
    Mersi, J.
    Bittrich, M.
    Seifert, F.
    Haider, M. S.
    Einsele, H.
    Rasche, L.
    Kampik, D.
    Kortuem, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 311 - 311
12345